您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cilazapril Monohydrate(Ro 31-2848)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cilazapril Monohydrate(Ro 31-2848)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cilazapril Monohydrate(Ro 31-2848)图片
CAS NO:92077-78-6
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)435.51
FormulaC22H31N3O5.H2O
CAS No.92077-78-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 87 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 87 mg/mL (199.8 mM)
SMILESO=C([C@@H]1CCCN2N1C([C@@H](N[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCC2)=O)O.O
SynonymsRo 31-2848 monohydrate; Ro31-2848 monohydrate; Ro-31-2848 monohydrate; Ro-31 2848 monohydrate;
实验参考方法
In Vitro

In vitro activity: Cilazapril is one of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension.

In VivoCilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats.
Animal modelRats
Formulation & Dosage1 mg/kg
References

J Pharmacol Sci. 2004 Jan;94(1):67-72; Life Sci. 1999;64(3):PL27-39.